Dapa has been applied globally for treating type 2 diabetes and the positive efficacy of Dapa in cardiovascular disease recommends the SGLT2 inhibitors in HFrEF treatment in the international heart failure guidelines [25, 26]. Here, SLC5A2 is linked to cardiovascular disorder.